Table 8
Studies correlating neoangiogenesis and survival in NSCLC
| First author | Year | Number of patients | Stage | Factor | Correlation |
|---|---|---|---|---|---|
| NS, not significant; NSCLC, non-small cell lung cancer; S, significant; VEGF, vascular endothelial growth factor. | |||||
| Giatromanolaki6 | 1997 | 134 | I, II | CD31 | NS |
| Pastorino8 | 1997 | 137 | I | CD31 | NS |
| Fontanini9 | 1997 | 407 | I–III | CD34 | S |
| Duarte26 | 1998 | 106 | I | VIII, CD31 | S, NS |
| Imoto27 | 1998 | 91 | I–III | VEGF | S |
| Matsuyama11 | 1998 | 101 | I–III | CD34 | S |
| Decaussin12 | 1999 | 81 | I, II | VEGF | NS |
| Kakolyris13 | 1999 | 69 | I, II | CD31 | S |
| Yano5 | 2000 | 108 | I–IV | CD34, VEGF | S, NS |
| Koukourakis10 | 2001 | 102 | I, II | VEGF | S |
| Han14 | 2001 | 85 | I | VEGF | S |
| Offersen7 | 2001 | 143 | I–III | VEGF, CD34 | NS, NS |
| Tanaka15 | 2001 | 236 | I–III | CD105, CD34 | S, NS |
